2024-04-29 16:48:22 ET
Summary
- Fate Therapeutics has a lot of potential in the cell therapy market, with multiple pipeline projects in development.
- Their flagship allogeneic CAR T-cell project, FT819, has shown promising results in early reports, particularly in patients with B-cell lymphoma.
- The company is also developing NK cell immunotherapies, with one program, FT522, showing positive results in patients with B-cell lymphoma. However, their cash burn rate remains high, which could be a risk.
...
Read the full article on Seeking Alpha
For further details see:
Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom